Malaysian pharmaceutical Duopharma Biotech achieved their best financial performance to date in 2022, reaching record highs for revenue and profit. However 2023 was not as kind, with profit after tax falling by 25% despite top line growth. How are they looking to reverse course in 2024? We discuss strategy with Group Managing Director Leonard Ariff Abdul Shatar.

<p>Malaysian pharmaceutical Duopharma Biotech achieved their best financial performance to date in 2022, reaching record highs for revenue and profit. However 2023 was not as kind, with profit after tax falling by 25% despite top line growth. How are they looking to reverse course in 2024? We discuss strategy with Group Managing Director Leonard Ariff Abdul Shatar.</p>

Sharper and stronger than a double espresso. The Morning Run stretches your mind and braces you for the business day. It's your fast track into work where you can hit the ground running. From 6am to 10am weekdays, the Morning Run brings you the biggest stories and must-listen-to interviews. Stay enlightened, make educated business and investment decisions.

The Breakfast Grille

Featuring the cream-of-the-crop as well as the controversial, the Breakfast Grille is the flagship show of BFM. Expect no-holds-barred interviews to get to the truth and into the minds of business leaders, policymakers and changemakers.

Advertisement